alendronate has been researched along with Hereditary Autoinflammation Diseases in 1 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Excerpt | Relevance | Reference |
---|---|---|
" We report on a 35-year-old female who was diagnosed with TRAPS, after finding the V95M mutation on the TNFRSF1A gene; who was treated in order with etanercept, anakinra, and canakinumab (150 mg/every 8 weeks by subcutaneous injection, then increased to 150 mg every 4 weeks); and who started therapy with oral alendronate (70 mg/weekly) to control her osteoporosis." | 3.81 | Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. ( Cantarini, L; Frediani, B; Iannone, F; Lopalco, G; Rigante, D; Vitale, A, 2015) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lopalco, G | 1 |
Rigante, D | 1 |
Vitale, A | 1 |
Frediani, B | 1 |
Iannone, F | 1 |
Cantarini, L | 1 |
1 other study available for alendronate and Hereditary Autoinflammation Diseases
Article | Year |
---|---|
Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate.
Topics: Adult; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Drug Therapy, Combina | 2015 |